Document is current
Any future updates will be listed below
-
Authors
Tsao, Nicole https://orcid.org/0000-0002-9670-0145
Hou, Qiang https://orcid.org/0000-0001-9879-7457
Chen, Shih-Yin https://orcid.org/0000-0001-9029-8362
Messe, Steven R. https://orcid.org/0000-0003-3108-5441
-
Funding
Funding for this research was provided by:
biogen
- License Information
-
More Information
Article History
Accepted: 25 July 2021
First Online: 22 August 2021
Declarations
:
: This study was funded by Biogen.
: Nicole Tsao was an employee of Biogen at the time of the study and owns stock in Biogen. Qiang Hou and Shih-Yin Chen are employees of and own stock in Biogen. Steven R. Messe is the local Principal Investigator for the Biogen CHARM trial to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (NCT02864953).
: This article does not contain any studies with human participants performed by any of the authors.
: Not applicable.
: Not applicable.
: Data used in this study are commercially available from IBM MarketScan.
: Software application or custom code.
: NT and S-YC provided the study concept and design. Data acquisition and analysis were performed by NT, S-YC and QH. All authors interpreted the results, and contributed to the development of the first draft, commented on previous versions, and approved the final manuscript.
